SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001308179-26-000341
Proxy solicitation materials
Actionable Insight • Neutral

This is a standard proxy filing. Monitor the company's website or future filings for the full proxy statement (DEF 14A) to see the specific voting items, such as director nominees and executive pay proposals, ahead of the shareholder meeting.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$744.35
T+0 close · Apr 24, 2026 · via day close
Latest settled
−12.52%
T+60 · $651.18
Vs SPY
−17.02%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $744.35entry
  2. T+1 · 7mo ago −2.01%α −1.53% · $729.36
  3. T+5 · 7mo ago −4.72%α −5.12% · $709.19
  4. T+20 · 6mo ago −14.74%α −19.70% · $634.62
  5. T+60 · 4mo ago −12.52%α −17.02% · $651.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron Pharmaceuticals has filed definitive additional proxy soliciting materials (DEFA14A) with the SEC. This is a routine filing related to an upcoming shareholder vote, likely covering items such as director elections, executive compensation, or other corporate governance matters. The filing is from the registrant and is definitive, indicating that the final details for the vote have been provided to shareholders. There is no indication of activist involvement or contentious issues.

Key Facts

  • Company: Regeneron Pharmaceuticals, Inc. (REGN)
  • Form Type: DEFA14A (Definitive Additional Proxy Soliciting Materials)
  • Filing Status: Filed by the Registrant, Definitive
  • No activist involvement (SC 13D) or dissident campaign indicated
  • Filing is routine and administrative in nature

Financial Impact

No direct financial impact from this filing

Risk Factors

  • None identified from this specific filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001308179-26-000341
Document: 0001308179-26-000341-index-headers.html0001308179-26-000341
Document: 0001308179-26-000341-index.html0001308179-26-000341
Document: 0001308179-26-000341.txt0001308179-26-000341

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (9h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026